We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ALGS

News List

CANbridge signs license agreement with Mirum for maralixibat in Greater China pharmaceutical-business-review
May 07, 2021
Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China.
Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access P drugs.com
September 23, 2020
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that it has submitted the first portion of its rolling New Drug ...